Announcements
- Immatics Announces Full Year 2023 Financial Results and Corporate Update
- Immatics Announces Pricing of $175 Million Public Offering
- Immatics Announces Proposed Public Offering
- Immatics Announces Third Quarter 2023 Financial Results and Business Update
- Immatics Reports Interim Clinical Data from ACTengine® IMA203 and IMA203CD8 TCR-T Monotherapies Targeting PRAME in an Ongoing Phase 1 Trial
- Immatics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for ACTengine® IMA203 TCR-T Monotherapy
- Moderna und Immatics geben strategische Multi-Plattform-Kollaboration zur Entwicklung innovativer Onkologie Therapeutika bekannt
- Moderna and Immatics Announce Strategic Multi-Platform Collaboration to Develop Innovative Oncology Therapeutics
- Immatics veröffentlicht Ergebnisse des zweiten Quartals 2023 sowie ein Update zur Geschäftsentwicklung
- Immatics Announces Second Quarter 2023 Financial Results and Business Update
More ▼
Key statistics
As of last trade Immatics NV (4A3:BER) traded at 9.34, -23.61% below its 52-week high of 12.22, set on Sep 11, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 9.15 |
---|---|
High | 9.39 |
Low | 9.14 |
Bid | 9.26 |
Offer | 9.48 |
Previous close | 9.17 |
Average volume | 2.25k |
---|---|
Shares outstanding | 102.99m |
Free float | 73.04m |
P/E (TTM) | -- |
Market cap | 1.01bn USD |
EPS (TTM) | -1.29 USD |
Data delayed at least 15 minutes, as of Apr 26 2024 19:30 BST.
More ▼